The main purpose of this study is to explore the improvement of renal function before and after the intervention of dorzagliatin in patients with type 2 diabetes.
Age:18-75 years old, male and female.
Patients with type 2 diabetes mellitus, type 2 diabetes mellitus diagnosis criteria: according to the "Chinese Type 2 Diabetes Mellitus Prevention and Treatment Guide (2020 Edition).
UACR 30-299mg/g.
eGFR ≥60mL/min/1.73m².
Pregnant and lactating women and women of childbearing age who do not want to take reliable contraceptive measures.
Known allergic history to dorzagliatin/gliclazide/metformin.
Diabetic acute and chronic complications, including diabetic ketoacidosis, a hyperglycemic hyperosmolar state or hypoglycemic coma, etc.
Serious impairment of heart, liver, kidney and other organs.
Yan Bi
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor institution